ES2304913T1 - Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. - Google Patents

Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano. Download PDF

Info

Publication number
ES2304913T1
ES2304913T1 ES07108593T ES07108593T ES2304913T1 ES 2304913 T1 ES2304913 T1 ES 2304913T1 ES 07108593 T ES07108593 T ES 07108593T ES 07108593 T ES07108593 T ES 07108593T ES 2304913 T1 ES2304913 T1 ES 2304913T1
Authority
ES
Spain
Prior art keywords
xanthan gum
ophthalmic composition
composition according
ophthalmic
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES07108593T
Other languages
English (en)
Other versions
ES2304913T3 (es
Inventor
Maria Grazia Mazzone
Grazia Paladino
Clara Marino
Ornella Peri
Vincenzo Enea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIFI SpA
Original Assignee
SIFI SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIFI SpA filed Critical SIFI SpA
Publication of ES2304913T1 publication Critical patent/ES2304913T1/es
Application granted granted Critical
Publication of ES2304913T3 publication Critical patent/ES2304913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/723Xanthans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)

Abstract

Goma de xantano para uso oftálmico como principio activo en un medicamento.

Claims (18)

1. Goma de xantano para uso oftálmico como principio activo en un medicamento.
2. Uso de goma de xantano como principio activo de un medicamento para la producción de un remedio para el tratamiento de heridas epiteliales oftálmicas.
3. Uso de goma de xantano de acuerdo con la reivindicación 2 en asociación con un medicamento seleccionado entre antiinfecciosos, antiinflamatorios, anestésicos y midriáticos.
4. Uso de goma de xantano de acuerdo con cualquiera de las reivindicaciones 2 o 3, en el que dicho epitelio es el epitelio corneal.
5. Uso de goma de xantano de acuerdo con cualquiera de las reivindicaciones 2 a 4 para promover la proliferación de células epiteliales.
6. Composición oftálmica re-epitelizante sustancialmente en forma de gel preformado que consiste en goma de xantano como principio activo y aditivos farmacológicamente aceptables.
7. Composición oftálmica de acuerdo con la reivindicación 6, en la que dicho principio activo comprende goma de xantano en cantidades entre 0,7% y 5% del volumen total de dicho gel preformado.
8. Composición oftálmica de acuerdo con la reivindicación 6, en la que dicha goma de xantano está presente en cantidades entre 0,8% y 3% del volumen total del gel preformado.
9. Composición oftálmica de acuerdo con la reivindicación 6, en la que dicha goma de xantano está presente en cantidades entre 0,9% y 1,5% del volumen total del gel preformado.
10. Composición oftálmica de acuerdo con cualquiera de las reivindicaciones 6 a 9, en la que dichos aditivos incluyen agentes isotónicos, tampones, disolventes, antioxidantes, agente de regulación del pH y similares.
11. Composición oftálmica de acuerdo con la reivindicación 10, en la que dichos agentes isotónicos pueden ser iónicos o no iónicos y su mezcla, los tampones pueden ser fosfato o borato, acetato, citrato/acetato, TrisHCl, o basados en histidina o arginina, los antioxidantes pueden ser citrato sódico, ascorbato o sulfato, los agentes reguladores del pH pueden ser ácidos o bases orgánicos o inorgánicos también junto con sus formas de sales, los disolventes o vehículos pueden ser agua o una mezcla de aceite/agua.
12. Composición oftálmica que consiste en:
1
\newpage
13. Composición oftálmica que consiste en:
2
\vskip1.000000\baselineskip
14. Composición oftálmica que consiste en:
3
\vskip1.000000\baselineskip
15. Composición oftálmica que consiste en:
4
\vskip1.000000\baselineskip
16. Método para la preparación de una composición oftálmica re-epitelizante de acuerdo con cualquiera de las reivindicaciones 6 a 15, que incluye las fases de:
- disolver la cantidad adecuada de aditivos en un volumen adecuado de agua;
- añadir, como se requieran, otros agentes farmacológicos;
- esterilizar dicha disolución;
- dispersar en un volumen adecuado de agua una cantidad predeterminada de goma de xantano sin agitación para evitar la formación de conglomerados;
- esterilizar dicha dispersión;
- añadir a la dispersión de goma de xantano la disolución de aditivos finalmente añadidos con agentes farmacológicos y agitar evitando turbulencia;
- distribuir de forma aséptica el gel obtenido en las fases precedentes en recipientes apropiados.
17. Método de acuerdo con la reivindicación 16, en el que la fase de dispersión de goma de xantano tiene lugar mediante homogeneización.
18. Composición oftálmica de acuerdo con una cualquiera de las reivindicaciones 6-15, que tiene una función mecánicamente protectora.
ES07108593T 2002-04-30 2002-04-30 Composiciones farmacéuticas reepitelializantes que contienen goma de xantano. Expired - Lifetime ES2304913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02425274A EP1358883B8 (en) 2002-04-30 2002-04-30 Re-epithelializing pharmaceutical compositions containing xanthan gum

Publications (2)

Publication Number Publication Date
ES2304913T1 true ES2304913T1 (es) 2008-11-01
ES2304913T3 ES2304913T3 (es) 2012-03-01

Family

ID=28799773

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02425274T Expired - Lifetime ES2290264T3 (es) 2002-04-30 2002-04-30 Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano.
ES07108593T Expired - Lifetime ES2304913T3 (es) 2002-04-30 2002-04-30 Composiciones farmacéuticas reepitelializantes que contienen goma de xantano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02425274T Expired - Lifetime ES2290264T3 (es) 2002-04-30 2002-04-30 Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano.

Country Status (15)

Country Link
US (5) US8912164B2 (es)
EP (2) EP1913948B1 (es)
JP (2) JP4837912B2 (es)
CN (1) CN100502884C (es)
AT (2) ATE367165T1 (es)
AU (1) AU2003230224B2 (es)
BR (1) BR0304655A (es)
CA (2) CA2749172C (es)
DE (2) DE07108593T1 (es)
DK (1) DK1358883T3 (es)
ES (2) ES2290264T3 (es)
MX (1) MXPA04010668A (es)
PT (1) PT1358883E (es)
RU (1) RU2297230C2 (es)
WO (1) WO2003092706A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE07108593T1 (de) * 2002-04-30 2008-12-04 Sifi S.P.A., Lavinaio-Aci Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten
BR0309890A (pt) 2002-05-09 2005-05-10 Medigenes Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação
JP4948176B2 (ja) * 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
KR101381035B1 (ko) 2006-03-23 2014-04-04 센주 세이야꾸 가부시키가이샤 잔탄검 및 글루코스를 포함하는 안약 조성물
EP2309980A1 (en) * 2008-07-08 2011-04-20 S.I.F.I. Societa' Industria Farmaceutica Italiana Ophthalmic compositions for treating pathologies of the posterior segment of the eye
JP5620168B2 (ja) * 2010-06-30 2014-11-05 Dsp五協フード&ケミカル株式会社 キシログルカン−カチオン複合体及びそれを含有する安定化組成物
IT1404145B1 (it) * 2010-12-27 2013-11-15 Altergon Sa Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi
EP2783689B1 (en) * 2011-11-24 2019-09-25 Toyo Sugar Refining Co., Ltd. Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent
KR102588589B1 (ko) * 2015-05-18 2023-10-16 히데미 카키하라 항균 물질 및 액상 항균제 및 액상 항균제의 제조 방법
RU2767913C2 (ru) 2015-12-29 2022-03-22 Интервет Интернэшнл Б.В. Вакцина от кокцидиоза
CN106236704A (zh) * 2016-08-30 2016-12-21 上海昊海生物科技股份有限公司 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法
CN114245737A (zh) 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物
IT202000002296A1 (it) * 2020-02-06 2021-08-06 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia
MX2021003369A (es) * 2021-03-22 2022-09-23 Laboratorios Grin S A De C V Lágrima ocular triple.
IT202200000821A1 (it) * 2022-01-19 2023-07-19 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4826872A (en) 1986-12-03 1989-05-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treatment of cataract
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JPH0651638B2 (ja) * 1989-02-13 1994-07-06 新技術事業団 角膜上皮創傷治療用点眼剤
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US6277365B1 (en) * 1997-09-18 2001-08-21 Bausch & Lomb Incorporated Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
DE20022450U1 (de) * 1999-01-19 2002-01-17 Mann Gerhard Chem Pharm Fab Künstliche Tränenflüssigkeit in Gelform
EP1318819A4 (en) * 2000-08-23 2006-03-15 Phairson Medical Inc TREATMENTS OF TRAUMAS AND OTHER INDICATIONS
US6919321B2 (en) * 2000-12-20 2005-07-19 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
DE07108593T1 (de) * 2002-04-30 2008-12-04 Sifi S.P.A., Lavinaio-Aci Reepithelialisierende pharmazeutische Zusammensetzungen, die Xanthangummi enthalten

Also Published As

Publication number Publication date
US20080146530A1 (en) 2008-06-19
US20080139502A1 (en) 2008-06-12
JP2011102315A (ja) 2011-05-26
CA2749172C (en) 2013-04-09
JP4837912B2 (ja) 2011-12-14
DK1358883T3 (da) 2007-11-12
US8912164B2 (en) 2014-12-16
CA2749172A1 (en) 2003-11-13
DE07108593T1 (de) 2008-12-04
EP1913948B1 (en) 2011-10-12
ES2304913T3 (es) 2012-03-01
RU2297230C2 (ru) 2007-04-20
CA2484020C (en) 2011-10-25
CN1649602A (zh) 2005-08-03
JP2005529906A (ja) 2005-10-06
BR0304655A (pt) 2004-07-20
JP5203472B2 (ja) 2013-06-05
RU2004131550A (ru) 2005-06-10
US20080139522A1 (en) 2008-06-12
WO2003092706A1 (en) 2003-11-13
CA2484020A1 (en) 2003-11-13
EP1358883B8 (en) 2007-10-03
ES2290264T3 (es) 2008-02-16
ATE367165T1 (de) 2007-08-15
EP1358883B1 (en) 2007-07-18
EP1913948A1 (en) 2008-04-23
US20050234011A1 (en) 2005-10-20
CN100502884C (zh) 2009-06-24
DE60221227T2 (de) 2008-01-31
MXPA04010668A (es) 2005-06-20
ATE528009T1 (de) 2011-10-15
PT1358883E (pt) 2007-10-01
DE60221227D1 (de) 2007-08-30
US20160166601A1 (en) 2016-06-16
AU2003230224B2 (en) 2008-07-17
AU2003230224A1 (en) 2003-11-17
EP1358883A1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
ES2304913T1 (es) Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano.
US9555045B2 (en) Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
ES2574757T3 (es) Vehículos oftálmicos de liberación controlada
Almeida et al. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations
ES2094688B1 (es) Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
ES2160803T3 (es) Composicion farmaceutica de aplicacion topica, su procedimiento de produccion y su utilizacion.
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
KR20040073503A (ko) 안과용 및 이과용 약제학적 조성물의 점도 및 기타물리학적 성질을 개질시키기 위한 무기 나노입자의 용도
KR20190049931A (ko) 무자극성 안과용 포비돈-요오드 조성물
GB2581656A (en) Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
JP2013543481A5 (es)
CN102481268B (zh) 眼科用组合物和白浊、沉淀的抑制方法
JP2024061871A (ja) 眼科組成物
ES2321875T3 (es) Preparacion oftalmica esteril,multifase, sin emulsionante aplicable en gotas.
PE20060484A1 (es) Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
Cucina et al. Dual 0.02% chlorhexidine digluconate–0.1% disodium EDTA loaded thermosensitive ocular gel for Acanthamoeba keratitis treatment
ES2197781B1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
CN105283186A (zh) 氯苯那敏或其盐的稳定化方法
TW201350124A (zh) 用於治療、控制、改善或逆轉乾眼症之病狀之醫藥組合物及方法
JPH0296515A (ja) 点眼液
CN105025896A (zh) 澄清的水性液体制剂
ES2225573T3 (es) Composiciones farmaceuticas que contienen tobramicina y goma xantana.
RU2533276C1 (ru) Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола и таурина, содержащие композицию витаминов группы в
ES2377342T3 (es) Remedio para enfermedades corneales
JP2019189607A (ja) 眼科組成物